540 related articles for article (PubMed ID: 31348549)
1. Cancer outcomes among Parkinson's disease patients with leucine rich repeat kinase 2 mutations, idiopathic Parkinson's disease patients, and nonaffected controls.
Agalliu I; Ortega RA; Luciano MS; Mirelman A; Pont-Sunyer C; Brockmann K; Vilas D; Tolosa E; Berg D; Warø B; Glickman A; Raymond D; Inzelberg R; Ruiz-Martinez J; Mondragon E; Friedman E; Hassin-Baer S; Alcalay RN; Mejia-Santana H; Aasly J; Foroud T; Marder K; Giladi N; Bressman S; Saunders-Pullman R
Mov Disord; 2019 Sep; 34(9):1392-1398. PubMed ID: 31348549
[TBL] [Abstract][Full Text] [Related]
2. Higher frequency of certain cancers in LRRK2 G2019S mutation carriers with Parkinson disease: a pooled analysis.
Agalliu I; San Luciano M; Mirelman A; Giladi N; Waro B; Aasly J; Inzelberg R; Hassin-Baer S; Friedman E; Ruiz-Martinez J; Marti-Masso JF; Orr-Urtreger A; Bressman S; Saunders-Pullman R
JAMA Neurol; 2015 Jan; 72(1):58-65. PubMed ID: 25401981
[TBL] [Abstract][Full Text] [Related]
3. Clustering of motor and nonmotor traits in leucine-rich repeat kinase 2 G2019S Parkinson's disease nonparkinsonian relatives: A multicenter family study.
Mestre TA; Pont-Sunyer C; Kausar F; Visanji NP; Ghate T; Connolly BS; Gasca-Salas C; Kern DS; Jain J; Slow EJ; Faust-Socher A; Kasten M; Wadia PM; Zadikoff C; Kumar P; de Bie RM; Thomsen T; Lang AE; Schüle B; Klein C; Tolosa E; Marras C
Mov Disord; 2018 Jul; 33(6):960-965. PubMed ID: 29665080
[TBL] [Abstract][Full Text] [Related]
4. Prevalence of cancer in Parkinson's disease related to R1441G and G2019S mutations in LRRK2.
Ruiz-Martínez J; de la Riva P; Rodríguez-Oroz MC; Mondragón Rezola E; Bergareche A; Gorostidi A; Gago B; Estanga A; Larrañaga N; Sarasqueta C; López de Munain A; Martí Massó JF
Mov Disord; 2014 May; 29(6):750-5. PubMed ID: 24357540
[TBL] [Abstract][Full Text] [Related]
5. Increased peripheral inflammation in asymptomatic leucine-rich repeat kinase 2 mutation carriers.
Dzamko N; Rowe DB; Halliday GM
Mov Disord; 2016 Jun; 31(6):889-97. PubMed ID: 26917005
[TBL] [Abstract][Full Text] [Related]
6. Motor and nonmotor heterogeneity of LRRK2-related and idiopathic Parkinson's disease.
Marras C; Alcalay RN; Caspell-Garcia C; Coffey C; Chan P; Duda JE; Facheris MF; Fernández-Santiago R; Ruíz-Martínez J; Mestre T; Saunders-Pullman R; Pont-Sunyer C; Tolosa E; Waro B;
Mov Disord; 2016 Aug; 31(8):1192-202. PubMed ID: 27091104
[TBL] [Abstract][Full Text] [Related]
7. Motor and non-motor features of Parkinson's disease in LRRK2 G2019S carriers versus matched controls.
Gunzler SA; Riley DE; Chen SG; Tatsuoka CM; Johnson WM; Mieyal JJ; Walter EM; Whitney CM; Feng IJ; Owusu-Dapaah H; Mittal SO; Wilson-Delfosse AL
J Neurol Sci; 2018 May; 388():203-207. PubMed ID: 29627023
[TBL] [Abstract][Full Text] [Related]
8. Analysis of macroautophagy related proteins in G2019S LRRK2 Parkinson's disease brains with Lewy body pathology.
Mamais A; Manzoni C; Nazish I; Arber C; Sonustun B; Wray S; Warner TT; Cookson MR; Lewis PA; Bandopadhyay R
Brain Res; 2018 Dec; 1701():75-84. PubMed ID: 30055128
[TBL] [Abstract][Full Text] [Related]
9. Exhaustion of mitochondrial and autophagic reserve may contribute to the development of LRRK2
Juárez-Flores DL; González-Casacuberta I; Ezquerra M; Bañó M; Carmona-Pontaque F; Catalán-García M; Guitart-Mampel M; Rivero JJ; Tobias E; Milisenda JC; Tolosa E; Marti MJ; Fernández-Santiago R; Cardellach F; Morén C; Garrabou G
J Transl Med; 2018 Jun; 16(1):160. PubMed ID: 29884186
[TBL] [Abstract][Full Text] [Related]
10. Olfactory Dysfunction in Parkinson's Disease Patients with the LRRK2 G2385R Variant.
Cao M; Gu ZQ; Li Y; Zhang H; Dan XJ; Cen SS; Li DW; Chan P
Neurosci Bull; 2016 Dec; 32(6):572-576. PubMed ID: 27699718
[TBL] [Abstract][Full Text] [Related]
11. Differential Phospho-Signatures in Blood Cells Identify LRRK2 G2019S Carriers in Parkinson's Disease.
Garrido A; Santamaría E; Fernández-Irigoyen J; Soto M; Simonet C; Fernández M; Obiang D; Tolosa E; Martí MJ; Padmanabhan S; Malagelada C; Ezquerra M; Fernández-Santiago R
Mov Disord; 2022 May; 37(5):1004-1015. PubMed ID: 35049090
[TBL] [Abstract][Full Text] [Related]
12. Increased markers of cardiac vagal activity in leucine-rich repeat kinase 2-associated Parkinson's disease.
Carricarte Naranjo C; Marras C; Visanji NP; Cornforth DJ; Sanchez-Rodriguez L; Schüle B; Goldman SM; Estévez M; Stein PK; Lang AE; Jelinek HF; Machado A
Clin Auton Res; 2019 Dec; 29(6):603-614. PubMed ID: 31444591
[TBL] [Abstract][Full Text] [Related]
13. Investigating Voice as a Biomarker for Leucine-Rich Repeat Kinase 2-Associated Parkinson's Disease.
Arora S; Visanji NP; Mestre TA; Tsanas A; AlDakheel A; Connolly BS; Gasca-Salas C; Kern DS; Jain J; Slow EJ; Faust-Socher A; Lang AE; Little MA; Marras C
J Parkinsons Dis; 2018; 8(4):503-510. PubMed ID: 30248062
[TBL] [Abstract][Full Text] [Related]
14. Increased basal forebrain volumes could prevent cognitive decline in LRRK2 Parkinson's disease.
Batzu L; Urso D; Grothe MJ; Veréb D; Chaudhuri KR; Pereira JB
Neurobiol Dis; 2023 Jul; 183():106182. PubMed ID: 37286171
[TBL] [Abstract][Full Text] [Related]
15. Exploring cancer in
Warø BJ; Aasly JO
Brain Behav; 2018 Jan; 8(1):e00858. PubMed ID: 29568677
[TBL] [Abstract][Full Text] [Related]
16. Cognitive and behavioral symptoms in Parkinson's disease patients with the G2019S and R1441G mutations of the LRRK2 gene.
Somme JH; Molano Salazar A; Gonzalez A; Tijero B; Berganzo K; Lezcano E; Fernandez Martinez M; Zarranz JJ; Gómez-Esteban JC
Parkinsonism Relat Disord; 2015 May; 21(5):494-9. PubMed ID: 25840672
[TBL] [Abstract][Full Text] [Related]
17. Accumulation of mitochondrial 7S DNA in idiopathic and LRRK2 associated Parkinson's disease.
Podlesniy P; Puigròs M; Serra N; Fernández-Santiago R; Ezquerra M; Tolosa E; Trullas R
EBioMedicine; 2019 Oct; 48():554-567. PubMed ID: 31631040
[TBL] [Abstract][Full Text] [Related]
18. Cerebrospinal fluid biomarkers and clinical features in leucine-rich repeat kinase 2 (LRRK2) mutation carriers.
Vilas D; Shaw LM; Taylor P; Berg D; Brockmann K; Aasly J; Marras C; Pont-Sunyer C; Ríos J; Marek K; Tolosa E
Mov Disord; 2016 Jun; 31(6):906-14. PubMed ID: 27041685
[TBL] [Abstract][Full Text] [Related]
19. Penetrance estimate of LRRK2 p.G2019S mutation in individuals of non-Ashkenazi Jewish ancestry.
Lee AJ; Wang Y; Alcalay RN; Mejia-Santana H; Saunders-Pullman R; Bressman S; Corvol JC; Brice A; Lesage S; Mangone G; Tolosa E; Pont-Sunyer C; Vilas D; Schüle B; Kausar F; Foroud T; Berg D; Brockmann K; Goldwurm S; Siri C; Asselta R; Ruiz-Martinez J; Mondragón E; Marras C; Ghate T; Giladi N; Mirelman A; Marder K;
Mov Disord; 2017 Oct; 32(10):1432-1438. PubMed ID: 28639421
[TBL] [Abstract][Full Text] [Related]
20. Nonmotor symptoms in LRRK2 G2019S associated Parkinson's disease.
Gaig C; Vilas D; Infante J; Sierra M; García-Gorostiaga I; Buongiorno M; Ezquerra M; Martí MJ; Valldeoriola F; Aguilar M; Calopa M; Hernandez-Vara J; Tolosa E
PLoS One; 2014; 9(10):e108982. PubMed ID: 25330404
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
